Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. ("IMCD" or "Company"), a
global leading distribution partner, and formulator of speciality chemicals and
ingredients, today announces its first three months 2024 results.
HIGHLIGHTS

  * Gross profit of EUR 295 million (on a constant currency basis, equal to the
    first three months of 2023)
  * Operating EBITA decline of 15% to EUR 127 million (-13% on a constant
    currency basis)
  * Free cash flow of EUR 106 million (first three months of 2023: EUR 147
    million)
  * Cash earnings per share decline of 19% to EUR 1.41 (first three months of
    2023: EUR 1.74)
  * Successful completion of six acquisitions: Valuetree and CJ Shah in India,

Joli Foods in Colombia, RBD in China, Euro Chemo-Pharma/Biofresh in Malaysia and Gova in the Benelux
Valerie Diele-Braun, CEO: "In a volatile first quarter of the year, we faced
challenging conditions in some of our market segments, resulting in a lower
operating EBITA of EUR 127 million versus a very strong Q1 2023. Whilst our
acquisition pipeline and projects with principals and customers remain healthy
in all regions, current market dynamics continue to make future customer demand
difficult to predict. Our strong commercial teams, digital and logistics
infrastructure, combined with further driving operational excellence and cost
control, will deliver future growth and efficiencies."
Attached, the full press release in PDF format and the main visual.
Â